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Abstract
Abnormal patterns of HPA axis activation, under basal conditions and in response to stress, are found in individuals with
schizophrenia and bipolar disorder. Altered glucocorticoid receptor (GR) mRNA and protein expression in the dorsolateral
prefrontal cortex (DLPFC) in psychiatric illness have also been reported, but the cause of these abnormalities is not known.
We quantified expression of GR mRNA transcript variants which employ different 59 promoters, in 35 schizophrenia cases, 31
bipolar disorder cases and 34 controls. We also explored whether sequence variation within the NR3C1 (GR) gene is related
to GR mRNA variant expression. Total GR mRNA was decreased in the DLPFC in schizophrenia cases relative to controls
(15.1%, p,0.0005) and also relative to bipolar disorder cases (8.9%, p,0.05). GR-1B mRNA was decreased in schizophrenia
cases relative to controls (20.2%, p,0.05), while GR-1C mRNA was decreased in both schizophrenia and bipolar disorder
cases relative to controls (16.1% and 17.2% respectively, both p,0.005). A dose-dependent effect of rs10052957 genotype
on GR-1B mRNA expression was observed, where CC homozygotes displayed 18.4% lower expression than TC
heterozygotes (p,0.05), and 31.8% lower expression than TT homozygotes (p,0.005). Similarly, a relationship between
rs6190 (R23K) genotype and GR-1C expression was seen, with 24.8% lower expression in GG homozygotes than GA
heterozygotes (p,0.01). We also observed an effect of rs41423247 (Bcl1) SNP on expression of 67 kDa GRa isoform, the
most abundant GRa isoform in the DLPFC. These findings suggest possible roles for the GR-1B and GR-1C promoter regions
in mediating GR gene expression changes in psychotic illness, and highlight the potential importance of sequence variation
within the NR3C1 gene in modulating GR mRNA expression in the DLPFC.
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Introduction
Appropriate responses to stress, mediated by the hypothalamic-
pituitary-adrenal (HPA) axis, are fundamental to survival and
adaptation [1]. Conversely, inappropriate and prolonged stress
responses have been implicated in the onset and symptoms of
psychiatric illnesses including schizophrenia and bipolar disorder.
Among the possible mediators of the maladaptive stress response is
the glucocorticoid receptor (GR), which binds the HPA axis stress
hormone cortisol.
Multiple studies have identified abnormalities of GR in the
brains of individuals with schizophrenia and bipolar disorder.
Decreased expression of total GR mRNA is evident in the
dorsolateral prefrontal cortex (DLPFC) in schizophrenia [2,3], in
the temporal cortex, hippocampus and amygdala in schizophrenia
and bipolar disorder [2,4], and in the entorhinal cortex in bipolar
disorder [2]. At the protein level, increased abundance of a
truncated GRa isoform, putative GRa-D1, in the DLPFC in
schizophrenia and bipolar disorder has also been recently reported
by our group [3]. These abnormalities of GR expression occur in
the context of broader HPA axis dysregulation, which is observed
in many individuals with schizophrenia and bipolar disorder and is
characterised by increased cortisol secretion and diminished
dexamethasone suppression in the illnesses [5,6].
One of the possible mechanisms driving HPA axis dysfunction
and GR disturbances in psychiatric illness is genetic variation in
the GR (NR3C1) gene. GR gene polymorphisms have been shown
to impact HPA axis stress responsiveness [7–10], and may
contribute to an individual’s vulnerability to maladaptive stress
responses and to their propensity to develop psychiatric illness
[11]. This hypothesis is supported by evidence of association of
genetic polymorphisms in the GR gene with risk for bipolar
disorder [12] and major depression [13,14]. Other stress signalling
genes such as FKBP5 have also been implicated in bipolar
disorder [15,16]. In the GR gene, polymorphisms have been
identified within the coding, intronic and untranslated 59 and 39
regions. The mechanisms through which these polymorphisms
may mediate their effects on vulnerability to psychiatric illness
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may be linked to changes in GR mRNA levels in the human brain,
and that this may contribute to risk of developing psychiatric
illness.
Since multiple different promoters may be used to synthesise
alternative GR mRNA transcripts variants, examination of these
variants may provide clues about the mechanisms underlying GR
mRNA dysregulation in schizophrenia. Thus far, investigations of
GR mRNA expression in psychiatric illness have focused on total
GR mRNA abundance, employing Taqman qPCR probes or
riboprobes which do not distinguish between GR mRNA
transcript variants. As a result, little is known about the specific
mRNA transcripts which are altered in psychiatric illness.
Upstream of the GR gene (NR3C1) lie promoter regions which
regulate tissue-specific expression of the thirteen GR exon 1
mRNA variants identified to date [17–21] (Figure 1). Numerous
GR exon 1 mRNA variants are expressed in the human
hippocampus [17], but it is not known which variants are
expressed in other brain regions including the prefrontal cortex.
To date, while GR mRNA deficits have been identified in the
DLPFC in schizophrenia, the evidence for such deficits in the
DLPFC in bipolar disorder is inconclusive [2]. More generally,
some GR abnormalities and aspects of HPA axis dysfunction are
common to both schizophrenia and bipolar disorder, while other
abnormalities are distinct to each illness [2,4–6]. Examination of
GR mRNA transcripts variant expression may provide a targeted
means of identifying GR mRNA abnormalities in bipolar disorder,
thus contributing to an understanding of common and distinct
aspects of GR dysregulation in schizophrenia and bipolar disorder.
In this study, we explored GR splice variant mRNA expression
in the DLPFC in both schizophrenia and bipolar disorder, using a
cohort of 100 post-mortem samples. We sought to: 1) determine
which GR alternative 59 exons are employed in the adult human
DLPFC, 2) determine whether expression levels of these
alternative GR mRNA transcript variants are altered in
schizophrenia and/or bipolar disorder cases relative to controls;
and 3) explore whether NR3C1 polymorphisms may be associated
with GR mRNA transcript and GRa protein isoform expression
levels in human brain.
Results
Endpoint PCR detection of GR exon 1 transcript variants
Initially, to determine which specific GR exon 1 mRNA variants
were expressed in the frontal cortex, endpoint PCR was performed
with primers targeting GR transcripts containing exons 1A, 1B, 1C,
1D, 1E, 1F and 1H. The transcript variants GR-1B, GR-1C and
GR-1H were found to be strongly expressed in pooled DLPFC
cDNA (from schizophrenia, bipolar disorder and control cases)
(Figure 2A). GR-1E and GR-1F were weakly expressed in pooled
DLPFC cDNA, but were abundant in universal cDNA isolated
from a panel of human tissues (Figure 2B). GR-1A and GR-1D
could not be detected in DLPFC or universal cDNA (Figure 2C).
Primers/probestargetingGR-1B,GR-1C,GR-1D,GR-1E,GR-1F
and GR-1H were tested for use in qPCR analysis. Reliable
amplification of the GR-1D, GR-1E and GR-1F transcripts was not
achieved by qPCR, so we report quantitative analysis of pan GR,
GR-1B, GR-1C and GR-1H mRNA expression.
Figure 1. Structure of the GR gene (NR3C1). Map illustrates functional SNPs present in the gene and the generation of GR mRNA variants by
inclusion of various exon 1 s in the mRNA 59 UTR. SNP- single nucleotide polymorphism, UTR- untranslated region, b- base pairs, Chr- chromosome.
doi:10.1371/journal.pone.0031720.g001
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bipolar disorder
Next, we determined whether DLPFC expression levels of pan
GR, GR-1B, GR-1C and GR-1H mRNA transcripts were
influenced by cohort demographic variables in the 100 cases
analysed (Table 1). Pan GR and GR-1H mRNA expression did
not significantly correlate with age, RIN, brain pH, PMI or brain
weight. There were no significant correlations of GR-1-B and GR-
1C mRNA expression with age, RIN or PMI, but there were
significant positive correlations of GR-1B mRNA expression with
brain weight (r=0.25, p,0.05) and of GR-1C mRNA expression
with brain pH (r=0.22, p,0.05).
Analysis of pan GR mRNA revealed significant group
differences in expression according to diagnosis (ANOVA
F(2,92)=6.96, p,0.005). Pan GR mRNA expression in the
DLPFC was 15.1% lower in schizophrenia cases relative to
controls by LSD post-hoc test ( p,0.0005), and 8.9% lower in
schizophrenia cases relative to bipolar disorder cases (p,0.05;
Figure 3). The 6.8% decrease in bipolar disorder cases relative to
controls did not reach significance (p=0.11).
GR-1B and GR-1C mRNA transcript expression also differed
significantly between diagnostic groups. There was a significant
effect of diagnosis on GR-1B mRNA expression [ANCOVA F(2,
92)=3.16, p,0.05 (co-varying for brain weight); Figure 3B]. GR-
1B expression was significantly decreased (20.2%) in schizophrenia
cases relative to controls (p,0.05), and non-significantly decreased
(11.3%) in bipolar disorder cases relative to controls (p=0.18). A
significant effect of diagnosis on GR-1C mRNA transcript
expression was also observed [ANCOVA F(2, 91)=5.59,
p=0.005 (co-varying for brain pH); Figure 3C]. GR-1C mRNA
expression was significantly decreased in both schizophrenia
(16.1%) and bipolar disorder (17.2%) cases relative to controls
Figure 2. Endpoint PCR detection of GR exon 1 mRNA transcript variants in the DLPFC. A) strong amplification of GR-1B, GR-1C and GR-1H
variants was evident in DLPFC cDNA, B) weaker amplification of GR-1E and GR-1F variants was observed in the DLPFC, but strong amplification was
observedinuniversalhumancDNA,C)GR-1AandGR-1DvariantsweredetectedneitherintheDLPFCnorinuniversalcDNA.UNI-universalhumancDNA.
doi:10.1371/journal.pone.0031720.g002
Table 1. Demographic details of cases from the Stanley Array cohort used to quantify GR exon 1 mRNA transcript variant
expression.
Control group Bipolar disorder group Schizophrenia group
number of cases 34 31 35
age (years) 43.8 (31–60) 44.9 (19–64) 42.6 (19–59)
gender 9F, 25M 16F, 15M 9F, 26M
hemisphere 16L, 18R 17L, 14R 17L, 18R
pH 6.61+/20.27 6.46+/20.28 6.47+/20.24
PMI (hrs) 29.5+/213.0 36.6+/218.1 31.4+/215.5
RIN 8.30+/20.69 8.32+/20.84 8.47+/20.56
manner of death natural=34 natural=17, suicide=14 natural=28, suicide=7
age of onset (years) - 24.8+/29.0 21.3+/26.1
duration of illness (years) - 20.2+/29.9 21.3+/210.1
lifetime antipsychotics (fluphenazine equivalents, mg) - 10297+/223865 85004+/2100335
antidepressant use yes=0, no=34 yes=18, no=13 yes=9, no=26
smoking status (around time of death) yes=9, no=9, unknown=16 yes=14, no=6, unknown=11 yes=23, no=4, unknown=8
Abbreviations: M- male, F- female, L- left, R- right, PMI- post-mortem interval, RIN- RNA integrity number. Data quoted are mean (range) +/2 standard deviation.
doi:10.1371/journal.pone.0031720.t001
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effect on GR-1H mRNA expression (ANOVA F(2, 88)=2.26,
p=0.11; Figure 3D). In a planned comparison between bipolar
disorder cases and controls, GR-1H mRNA expression was 22.6%
lower in bipolar disorder cases than controls (p,0.05). There was
no significant difference in GR-1H mRNA between schizophrenia
cases and controls. Three schizophrenia cases were observed to
have substantially higher GR-1H mRNA expression than the
other schizophrenia cases in the cohort (Figure 3D), potentially
impacting our ability to identify group differences.
Expression levels of pan GR mRNA were highly significantly
correlated with levels of all GR exon 1 mRNA transcript variants
measured (GR-1B, r=0.69, p,1610
212; GR-1C, r=0.55,
p,1610
27; GR-1H, r=0.36, p,1610
23), suggesting that each
contributed significantly to overall pan GR mRNA levels.
Effects of suicide and other cohort demographic
variables on GR mRNA expression
The relationship between manner of death and DLPFC GR
mRNA transcript expression was investigated. When schizophre-
nia and bipolar disorder groups were subdivided according to
suicide status, significant group differences in pan GR mRNA
expression were observed (ANOVA (F(4, 90)=4.83, p,0.005).
Individuals with schizophrenia who had not died by suicide
(suicide-negative) displayed 14.7% lower pan GR mRNA levels
than individuals with schizophrenia who had died by suicide
(suicide-positive) (p=0.05) and 17.7% lower pan GR mRNA levels
than controls (all suicide-negative) (p,0.0001) (Figure 4A). There
was no difference in pan GR mRNA expression between suicide-
positive schizophrenia cases and controls. In bipolar disorder, no
differences between suicide-positive and suicide-negative cases
were observed.
A similar relationship between suicide and expression of all
individual GR mRNA transcript variants in schizophrenia cases
was observed. Expression of GR-1B mRNA (ANCOVA (F(4,
90)=2.79, p,0.05), GR-1C (ANCOVA (F(4, 89)=5.11, p,0.001)
and GR-1H mRNA (ANOVA (F(4, 87)=5.34, p,0.005) varied
significantly according to suicide status within diagnostic groups.
GR-1B expression of suicide-negative schizophrenia cases was
26.8% lower than suicide-positive schizophrenia cases (p,0.05),
and 25.8% lower than controls (p,0.005; Figure 4B). Similarly,
GR-1C expression of suicide-negative schizophrenia cases was
20.6% lower than suicide-positive schizophrenia cases (p,0.05),
and 20.0% lower than controls (p,0.0005; Figure 4C). In bipolar
disorder, GR-1C mRNA expression was also impacted by suicide
status, with 14.9% lower GR-1C mRNA levels in suicide-negative
bipolar disorder cases than suicide-positive cases (trend p=0.06),
and 23.5% lower than controls (p,0.0005). Finally, GR-1H
Figure 3. Expression of pan GR, GR-1B, GR-1C and GR-1H mRNA transcripts in the DLPFC. Control, bipolar disorder and schizophrenia cases
from the Stanley Array cohort were used. A) Pan GR mRNA expression was 15.1% lower in schizophrenia cases relative to controls (p,0.0005), and 8.9%
lower in schizophrenia cases relative to bipolar disorder cases (p,0.05). B) GR-1B mRNA expression also differed significantly between diagnostic groups,
with 20.2% lower GR-1B expression in schizophrenia cases than controls (p,0.05). C) GR-1C mRNA expression was significantly decreased in
schizophrenia(16.1%) andbipolar disorder(17.2%) cases relativetocontrols(both p,0.005). D)A significanteffectofdiagnosis GR-1H expressionwas not
observed, but a planned post-hoc test revealed a significant difference between bipolar disorder and control groups (p,0.05). Green, orange and blue
diamonds represent control, bipolar disorder and schizophrenia cases respectively.Red bars represent groupmeans.* p,0.05, **p,0.005,*** p,0.0005.
doi:10.1371/journal.pone.0031720.g003
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lower than suicide-positive schizophrenia cases (p,0.0005), and
27.5% lower than controls (p,0.05; Figure 4D).
The effects of other cohort demographic variables (Table 1) on
GR mRNA transcript variant expression were also explored. No
significance differences in pan GR, GR-1B, GR-1C or GR-1H
were observed due to brain hemisphere, gender or when
diagnostic groups were subdivided according to antidepressant
use. Possible differences in GR mRNA expression associated with
smoking were analysed using the 65 cases for whom smoking status
around time of death was known. There was no evidence of a
significant main effect of smoking at time-of-death on pan GR,
GR-1B, GR-1C or GR-1H mRNA levels. Within schizophrenia
cases only, pan GR and GR-1H mRNA levels were significantly
correlated with duration of illness (r=20.43, p,0.05 and
r=20.39, p,0.05 respectively). GR-1B and GR-1C transcripts
were not correlated with duration of illness. None of the transcripts
were significantly correlated with age of onset or fluphenazine-
equivalent lifetime antipsychotics within schizophrenia or bipolar
disorder groups.
NR3C1 gene polymorphisms in schizophrenia and
bipolar disorder
In order to explore genetic variation within the NR3C1 gene in
schizophrenia and bipolar disorder, the cohort was genotyped for
11 functional or promoter NR3C1 SNPs (Table 2). Two SNPs,
rs10482614 and rs6196 (N766N) showed significant genotype
frequency distortion via the Hardy-Weinberg equilibrium test.
The genotype frequency distortion of both these SNPs in the entire
cohort was driven by distortion in the schizophrenia group only,
with no significant distortion evident in control or bipolar disorder
groups. SNP rs1800445 (N363S) was non-polymorphic in this
largely Caucasian cohort.
Relationships between NR3C1 gene polymorphisms and
expression of GR mRNA transcripts and protein isoforms
A significant main effect of rs10052957 (Tth111l) genotype on
GR-1B mRNA expression was found (ANCOVA F(2, 81)=5.32,
p,0.001; Figure 5A). There was not a significant genotype6diag-
nosis interaction. By LSD post-hoc test, the GR-1B mRNA
expression of individuals with CC genotypes (n=46) was 18.4%
lower than those of individuals with TC genotypes (n=40;
p,0.05), and 31.8% lower than those with TT genotypes (n=9;
p,0.005). Thus, an allele dose effect on GR-1B mRNA expression
was observed. No significant main effects of rs10052957 genotype
on pan GR, GR-1C or GR-1H mRNA expression were seen (all
p.0.11).
For the rs6190 (R23K) SNP, a significant effect of genotype on
expression of GR-1C mRNA in the DLPFC was also observed
(Mann-Whitney U-test, z=2.58, p,0.01; Figure 5B). The GR-1C
mRNA expression of GG homozygotes (n=91) was 24.8% lower
than that of GA heterozygotes (n=4). A trend towards a main
effect of rs6190 genotype on expression of GR-1B mRNA was
observed (Mann-Whitney U-test, z=1.94, p=0.053). There was
Figure 4. Effect of suicide on expression of GR mRNA transcripts in the DLPFC. Suicide-positive and suicide-negative control cases, bipolar
disorder cases and schizophrenia cases were compared. A) Pan GR mRNA expression; B) GR-1B mRNA expression; C) GR-1C mRNA expression; D) GR-
1H mRNA expression. For all transcripts, GR transcript expression was decreased in suicide-negative schizophrenia cases relative to suicide-positive
schizophrenia cases and relative to controls (all suicide-negative). For the GR-1C mRNA transcript, expression was decreased in bipolar disorder as
well as schizophrenia in suicide-negative cases relative to both suicide-positive cases and controls. Green, orange and blue diamonds represent
control, bipolar disorder and schizophrenia cases respectively. Red bars represent group means. Abbreviations: BP- bipolar disorder, SCZ-
schizophrenia. * p#0.05, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0031720.g004
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GR or GR-1H mRNA transcripts.
Levels of GRa protein isoforms in the DLPFC have been
quantified and reported previously [3], and here were analysed
according to NR3C1 genotype as described above for GR mRNA
transcripts. In the DLPFC, five GRa immunoreactive (IR) bands
are consistently observed, with IR band 1 corresponding to full-
length GRa, IR band 2 to a 67 kDa GRa isoform, IR bands 3 and
4 to putative GRa-D N-terminal isoforms, and IR band 5 to a
25 kDa GRa isoform [3]. Significant differences in DLPFC GRa
IR band intensity according to rs41423247 (Bcl1) genotype were
identified (Figure 6). For rs41423247, significant main effects of
Table 2. Details of NR3C1 SNPs genotyped in this study.
dbSNP rs #
location (UCSC build
Hg19, Feb 2009) location, description, (common name) SNP (major/ minor allele) MAF HWE p-value
rs10052957 142786701 promoter; 2656 bases upstream of exon
1B (Tth111l)
C/T 0.320 1
rs72801094 142785905 promoter; 1860 bases upstream of exon 1B A/G 0.046 0.177
rs5871845 142783949 59 UTR; exon 1B -/C 0.052 1
rs10482614 142782402 promoter; between exon 1C and exon 1H G/A 0.134 0.012
rs10482616 142781567 promoter; between exon 1H and exon 2 G/A 0.113 0.342
rs4634384 142780697 promoter; between exon 1H and exon 2 G/A 0.490 0.687
rs6190 142780337 exon 2; non-synonymous (R23K) G/A 0.021 1
rs1800445 142779311 exon; non-synonymous (N363S) A/G 0 -
rs41423247 142778575 intron B; between exons 2 and 3, 647 bases
downstream of exon 2 (Bcl1)
C/G 0.345 0.825
rs6196 142661490 exon 9a; synonymous (N766N) T/C 0.139 0.017
rs6198 142657621 39 UTR; inside exon 9b (A3669G) A/G 0.170 0.065
Abbreviations: UCSC- University of California Santa Cruz, MAF- minor allele frequency, HWE- Hardy-Weinberg Equilibrium.
doi:10.1371/journal.pone.0031720.t002
Figure 5. Effects of rs10052957 (Tth111l) and rs6190 (R23K) genotypes on GR mRNA expression. A) A significant main effect of
rs10052957 genotype on GR-1B mRNA expression was identified (ANCOVA F(2, 81)=5.32, p,0.001), with significant decreases in GR-1B expression in
individuals with CC genotype (n=46) relative to those with TC genotype (n=40; 18.4% decrease, p,0.05) and TT genotype (n=9; 31.8% decrease,
p,0.005). B) An effect of rs6190 genotype on GR-1C mRNA expression was also observed (Mann-Whitney U-test, z=2.58, p,0.01), with a 24.8%
decrease in GG homozygotes (n=91) relative to GA heterozygotes (n=4). Error bars represent SEM. * p,0.05, ** p,0.005.
doi:10.1371/journal.pone.0031720.g005
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p,0.05) and total IR bands 1–5 (ANOVA F(2, 86)=3.28, p,0.05)
were seen. There were no significant genotype6diagnosis
interactions. By LSD post-hoc, IR band 2 (67 kDa GRa)
abundance was significantly decreased in rs41423247 GG
homozygotes (n=11; 26.5% decrease, p,0.05) and GC hetero-
zygotes (n=43; 23.4% decrease, p=0.006) relative to CC
homozygotes (n=41). A 15.1% decrease in total intensity of IR
bands 1–5 in GC heterozygotes relative to CC homozygotes was
also observed (p,0.05). No effects of rs4142324 genotype on IR
bands 1, 3, 4 or 5 were seen. No additional differences in GRa IR
band intensity were detected when samples were grouped
according to the other genotyped SNPs.
Discussion
In this study, we identified abnormalities of GR mRNA
expression in schizophrenia and bipolar disorder, which we
describe for first time in the context of variation within the
NR3C1 gene. In the DLPFC in schizophrenia cases, there was
decreased expression of pan GR mRNA and at least two mRNA
variants, GR-1B and GR-1C, which use alternative promoters. In
bipolar disorder, GR mRNA deficits were more limited, and
appeared to impact the GR-1C but not GR-1B mRNA transcript.
Changes in GR-1H mRNA were not conclusive, given that three
schizophrenia cases potentially obscured what would have
otherwise been significant decreases in GR-1H mRNA in both
schizophrenia and bipolar disorder.
These findings confirm and extend prior observations of GR
mRNA abnormalities in both schizophrenia and bipolar disorder.
Previous exploration of GR mRNA expression using a pan GR
riboprobe revealed a significant decrease in total GR mRNA in
the DLPFC in schizophrenia relative to controls [2]. In that study,
the decrease in total GR mRNA in bipolar disorder failed to reach
significance relative to controls, being less substantial than the
decrease observed in schizophrenia. The findings in this study are
consistent with that previous report, with significant decreases in
total GR mRNA in schizophrenia relative to both controls and
bipolar disorder cases, but only a small non-significant average
decrease in bipolar disorder relative to controls. By using primers/
probes specific to GR exon 1 mRNA transcript variants in this
study, we were able to determine that decreases in total GR
mRNA in schizophrenia arise due to combined deficits of more
than one GR exon 1 transcript variant. We were also able to
confirm that a specific GR mRNA deficit, restricted to the GR-1C
transcript, does exist in the DLPFC in bipolar disorder, although
this is not reflected in significantly decreased total GR mRNA
expression. This GR-1C deficit may be masked by other
unchanged transcripts (such as GR-1B) when quantifying total
GR mRNA in bipolar disorder. Indeed, our correlational analysis
suggested that GR-1B mRNA levels accounted for ,48% of
variance in pan GR mRNA levels in the DLPFC.
Our results also suggest that functional polymorphisms within
the GR (NR3C1) gene may impact GR gene expression. In
particular, GR-1B mRNA transcript variant expression may be
influenced by the rs10052957 (Tth111l) SNP. Carriers of the
rs10052957 major C allele displayed decreased GR-1B mRNA
expression in an allelic dose-dependent fashion. The rs10052957
SNP lies most proximal to the GR-1D transcription start site, but
still upstream of the alternative exon 1B, and is 793 bases
upstream of the putative NR3C1 proximal promoter region
[21,22]. It is possible that, located adjacent to the NR3C1
proximal promoter region, the C and T alleles of rs10052957 may
differentially facilitate GR-1B transcript expression. A protective
effect of the rs10052957 minor T allele has previously been
reported in bipolar disorder [12], with a lower frequency of the
CT genotype in bipolar disorder cases than controls, in a cohort of
245 cases and 320 controls. Seasonal patterns of hypomania in
bipolar disorder have also been associated with a haplotype
containing the rs10052957 SNP [23]. In our current study, allele
dose-dependent regulation of GR-1B expression by rs10052957
was not specific to schizophrenia cases, but was also observed in
bipolar disorder cases and controls. It is possible that rs10052957
genotype may have played a role in GR-1B mRNA down-
regulation in schizophrenia, since the major C allele of the
rs10052957 SNP was over-represented in schizophrenia cases in
our cohort (data not shown). However, because of the small size of
our cohort, it is not possible to conclude that the rs10052957 SNP
is contributing to decreased GR-1B mRNA expression in
schizophrenia cases relative to controls. Further work in larger
genetic samples will be needed to determine the possible
contribution of the rs10052957 SNP to altered GR-1B mRNA
levels in schizophrenia.
A second SNP, rs6190 (R23K), was also implicated in regulation
of GR mRNA expression. Individuals homozygous for the rs6190
Figure 6. Effect of rs41423247 (Bcl1) genotype on GRa protein expression in the DLPFC. There were significant main effects of genotype
on IR band 2 intensity (ANCOVA, F(2, 87)=4.85, p,0.05) and total IR bands 1–5 (ANOVA F(2, 86)=3.28, p,0.05). The abundance of IR band 2 (67 kDa
GRa) was significantly decreased in rs41423247 GG homozygotes (n=11; 26.5% decrease, p,0.05) and GC heterozygotes (n=43; 23.4% decrease,
p,0.01) relative to CC homozygotes (n=41). The total GRa abundance (IR bands 1–5) was decreased (15.1%) in GC heterozygotes relative to CC
homozygotes (p,0.05). * p,0.05, ** p=0.006.
doi:10.1371/journal.pone.0031720.g006
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GR-1C mRNA expression than individuals carrying the minor A
allele (SNP carriers). The rs6190 SNP is a non-synonymous coding
SNP located in codon 23 of exon 2, which results in the
substitution of an arginine (R) residue for a lysine (K) in the
translated receptor amino acid sequence [24]. It is often referred
to as ER22/23EK because it is linked to rs6189, a synonymous
SNP, in codon 22 [which codes for glutamic acid (E)]. In bipolar
disorder patients, the rs6190 SNP may impact illness course, with
carriers of the rs6190 SNP displaying an 8 year earlier onset of
their first hypomanic episode than non-carriers [23]. Previous
work has also revealed increased frequency of rs6190 carriers in
major depression [13,14], and somewhat paradoxically, a faster
response to antidepressant treatment among rs6190 carriers. It is
not clear how the R23K amino acid change impacts the cellular
actions of the receptor, or by what mechanism it may alter the
onset and course of bipolar disorder or confer vulnerability to
major depression. However, since the amino acid substitution
occurs in the primary receptor transactivation domain, it is
possible that the transcriptional activation of target genes by the
receptor may be altered by the SNP. The mechanism by which
rs6190 genotype may alter GR mRNA transcript expression is not
known.
We also report a main effect of the rs41423247 (Bcl1) SNP on
abundance of the 67 kDa GRa protein isoform. Carriers of the
minor G allele of rs41423247 displayed decreased 67 kDa GRa
isoform abundance relative to CC homozygotes. The rs41423247
SNP is located in intron B (between exons 2 and 3), 645 bases
downstream of exon 2. Rs41423247 has been shown to modulate
HPA axis function, with G carriers reported to have higher
baseline and peak ACTH levels and diminished responses to
antidepressants [25]. In addition, as part of a haplotype with
rs33388 and rs33389 in intron B, healthy G carriers display lower
post-dexamethasone cortisol levels [26]. GG homozygotes have
also been reported to have lower cortisol responses to psychosocial
stress, and be at increased risk of major depression [7,13].
Decreased abundance of the predominant DLPFC GRa receptor
isoform (67 kDa GRa) in GG homozygotes and G allele carriers
would be consistent with these findings, and may suggest a possible
mechanism though which rs41423247 genotype may impact HPA
axis function. Given that the 67 kDa GRa isoform was not altered
in schizophrenia and no diagnosis6genotype interaction was
observed, the rs41423247 polymorphism may be mediating effects
on HPA axis activity in general, independent of the pathogenesis
of schizophrenia or bipolar disorder.
Increased expression of pan GR, GR-1B and GR-1H mRNA
transcripts in suicide-positive schizophrenia cases relative to
suicide-negative schizophrenia cases was observed. This finding
replicates earlier qPCR results with pan GR mRNA in a different
schizophrenia cohort [3]. In our current study, a relationship
between suicide and GR mRNA expression was prominent in
schizophrenia, but limited to the GR-1C transcript variant in
bipolar disorder. Previous work, employing in situ hybridisation in
bipolar disorder cases, has also identified increased GR mRNA
expression in suicide-positive relative to suicide-negative bipolar
disorder cases in a third cohort [2]. Whether increased GR mRNA
expression is a biological risk factor for suicide in psychotic illness,
or reflects an interaction of illness pathology with altered stress
experiences prior to death by suicide remains to be determined.
The observed effect of suicide was most acute in the GR-1H
mRNA transcript variant. The two highest GR-1H mRNA
expressing schizophrenia cases, with substantially increased
expression levels (Figure 3), were suicide-positive, as were four
other high-expressing cases. Therefore, the differences in GR-1H
mRNA between diagnostic groups, which failed to reach
significance, may have been partially obscured by the high GR-
1H mRNA expression of suicide-positive cases.
One of the challenges associated with the use of human post-
mortem tissue is the possible confounding effect of factors such as
antipsychotic exposure, antidepressant use and smoking. In this
study, the lack of correlation between GR mRNA transcript levels
and estimated lifetime antipsychotics doses suggests that decreased
GR mRNA transcript expression in schizophrenia and bipolar
disorder may not be a direct consequence of antipsychotic drug
exposure. In our previous study, we also did not observe
correlation of pan GR mRNA levels with estimated daily, last or
lifetime antipsychotics doses [3]. Furthermore, although in vitro
work has characterised the effects of antidepressants on GR
transcription and function [27,28], such effects of antipsychotics
on GR have not been established [27]. In this study, when effects
of antidepressants were explored by subdividing and analysing the
schizophrenia and bipolar disorder groups according to antide-
pressant use, there were no significant differences between
antidepressant-positive and antidepressant-negative cases. No
significant main effects of smoking on GR mRNA expression
were seen. Further work is required to clarify the potential effects
of these confounding factors on GR mRNA expression in the
prefrontal cortex.
In this study, we observed that decreased GR-1C mRNA
expression was common to both schizophrenia and bipolar
disorder, while decreased pan GR and GR-1B mRNA expression
were present only in schizophrenia. This evidence is consistent
with other molecular, epidemiological and clinical evidence, which
also highlights similarities and differences between schizophrenia
and bipolar disorder. Psychotic features are common to both
bipolar I disorder and schizophrenia, as are some neuropatholog-
ical changes such as reduced hippocampal volume [29]. Some
early life experiences, such as early parental loss and childhood
abuse, are common risk factors for both schizophrenia and bipolar
disorder [30]. Abnormal cortisol secretion and dexamethasone
suppression have been observed in both disorders [5,6,31]. At the
molecular level, numerous mRNA transcripts and proteins are
altered in both schizophrenia and bipolar disorder, including
brain-derived neurotrophic factor (BDNF), glutamic acid decar-
boxylase-67 (GAD-67) and growth-associated protein-43 (GAP-43)
[32–38]. Some of these transcripts, such as BDNF and GAP-43,
are down-regulated by cortisol [39–41]. Increased abundance of
the truncated GRa-D1 isoform has been shown in the DLPFC in
both schizophrenia and bipolar disorder [3]. Some common
genetic factors have been shown to underlie schizophrenia and
bipolar disorder [42]. More work is required to understand
whether common patterns of GR expression (potentially involving
the GR-1C mRNA transcript) are related to common risk factors
for, or symptoms of, the two disorders. Schizophrenia and bipolar
disorder also display distinctive features. Affective symptoms are
displayed in bipolar disorder but not necessarily schizophrenia.
Some early life experiences, such as obstetric complications, are
risk factors for schizophrenia but possibly not for bipolar disorder
[43,44]. A number of neuropathological changes, such as
increased DLPFC neuron density, are observed in schizophrenia
but have not been detected in bipolar disorder [45,46]. Further
work is also required to determine whether the divergent patterns
of GR mRNA expression (potentially involving the GR-1B mRNA
transcript) in schizophrenia and bipolar disorder are related to
differences between the illnesses.
Overall, we provide further evidence of GR mRNA abnormal-
ities in schizophrenia and bipolar disorder, which involve the GR-
1B, 1C and 1H mRNA transcript variants. Our data also suggests
Glucocorticoid Receptor mRNA in Psychotic Illness
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e31720the potential involvement of NR3C1 polymorphisms, rs10052957
(Tth111l), rs6190 (R23K) and rs41423247 (Bcl1), which may play
a role in regulating the expression of the GR-1B mRNA transcript,
GR-1C mRNA transcript and 67 kDa GRa protein isoform
respectively. Experimental work in cell culture systems may clarify
regulatory effects of the NR3C1 polymorphisms on GR mRNA
transcripts and GRa protein isoforms. Further work in living
people with schizophrenia and in larger genetic samples will also
be needed to determine the link between GR gene variants, altered
brain mRNA levels and changes in stress responsiveness in
schizophrenia and bipolar disorder. Our data provide further
information on which genetic variants are likely to be the most
informative for future clinical studies.
Materials and Methods
Tissue collection
These studies were carried out in accordance with the
declaration of Helsinki, after approval by the Human Research
Ethics Committee at the University of NSW (#HREC07261).
Cases from the Stanley Foundation Array cohort were used
(Table 1). Genomic DNA and total RNA were extracted by the
Stanley Medical Research Institute (SMRI) from tissues from the
middle frontal gyrus. Genomic DNA was extracted using the
Promega Wizard genomic kit (Promega, Madison, WI) using
DLPFC tissues from 34 schizophrenia cases, 30 bipolar cases and
31 controls. Total mRNA was extracted with Trizol reagent
(Invitrogen, Carlsbad, CA) as previously described [47], using
tissues from all 35 schizophrenia cases, 31 bipolar cases and 34
controls. The quality of extracted total RNA was determined by
SMRI using the Agilent Bioanalyzer 2100 (Agilent Technologies,
Palo Alto, California). RNA quality was indicated by an RNA
integrity number (RIN) ranging from 0 (degraded) to 10 (very good
quality), and did not differ between diagnostic groups. Extracted
genomic DNA and total RNA were supplied by SMRI for
subsequent experiments.
PCR detection of GR exon 1 variants
Endpoint PCR was performed to amplify GR exon 1 mRNA
transcript variants in schizophrenia, bipolar disorder and control
cDNA (pooled from all cohort samples) from DLPFC tissue. For
targets not amplified in DLPFC cDNA, reactions were repeated
with universal human cDNA from normal human tissues (Biotaq,
Gaithersburg, MD). Primer sequences and reaction conditions are
shown in Table 3. Each reaction contained MgCl2 (2–4 mM),
dNTPs (0.2 mM), forward and reverse primers (0.2 mM), cDNA
(approximately 4.5 ng/ml) and RedHot DNA polymerase (0.5 U;
Thermo Scientific, Waltham, MA) in 16 reaction buffer. For
PCR, the reaction mix including cDNA was incubated at 94uC for
3 min, followed by 40 cycles of 94uC (30 s), 53–62uC (30 s, or 90 s
for GR-1Atotal) and 72uC (30 s), then 72uC for 10 min and 4uC
overnight. Products were run on a 1% agarose gel alongside a 1 kb
ladder (Fermentas, Waltham, MA), and visualised on the
Chemidoc XRS Molecular Imager (Bio-Rad, Hercules, CA).
Quantitative real-time PCR (qPCR) and endpoint PCR
analysis
For GR mRNA transcript quantification, qPCR analysis was
conducted as previously reported [48]. Briefly, cDNA was
synthesised from 3 mg total RNA from DLPFC tissue, using the
Superscript First-Strand Synthesis Kit (Invitrogen). Pre-designed
Taqman gene expression assays (Applied Biosystems, Foster City,
CA) targeting pan GR, GR-1B and GR-1Ctotal (henceforth simply
GR-1C) and GR-1D were used along with four ‘housekeeper’
genes: b-actin (ACTB), beta-2-microglobulin (B2M), TATA-
binding protein (TBP) and ubiquitin C (UBC). In addition,
custom Taqman primer/probes designed to target the exon 1–2
boundary of GR-1E, GR-1F and GR-1H were also used (Table 4).
No Taqman primer/probe for GR-1Atotal (henceforth simply GR-
1A) was designed or tested. Serial dilutions of cDNA, pooled from
all cohort samples, were included on every qPCR plate for
quantification of sample expression by the relative standard curve
method. ‘No template’ and ‘no reverse transcriptase’ controls were
included on each plate to rule out non-specific amplification.
For qPCR gene expression analysis, each sample was assayed in
triplicate. Raw expression data were normalised to the geometric
mean of four housekeeper genes, and population outliers excluded
if their normalized expression values were greater than 2 standard
deviations from the group mean. The raw expression levels of the
four housekeeper genes did not vary according to diagnosis when
analysed by ANOVA [TBP- F(2, 96)=0.30, p=0.74; UBC- F(2,
96)=0.93, p=0.40; ACTB- F(2, 96)=0.70, p=0.50; B2M F(2,
96)=0.10, p=0.90]. For each analysis, between 32–34 control
cases, 29–31 bipolar disorder cases and 31–34 schizophrenia cases
were retained after outlier removal.
Western blotting
Western blotting was performed using crude protein homoge-
nates from the DLPFC of 35 schizophrenia cases, 34 bipolar cases
and 35 controls. Seven micrograms of protein homogenate was
heated (95uC, 5 min), run on 10% bis-tris polyacrylamide gels
Table 3. Endpoint PCR primers used for detection of GR exon 1 mRNA transcript variants.
target transcript reference annealing temps MgCl2 (mM) forward primer sequence reverse primer sequence
GR-Atotal Breslin 2001 56–60 2 ATCACTTTCACTTCTGCTGG CAGTGGATGCTGAACTCTTGG
GR-1B Turner 2005 55 2 GCCGGCACGCGACTCC CAGTGGATGCTGAACTCTTGG
GR-1Ctotal Turner 2005 53 2 GCTCCTCTGCCAGAGTTGAT CAGTGGATGCTGAACTCTTGG
GR-1C2 Turner 2005 55 2 TCTGTCTGTGACGGATTCTGC CAGTGGATGCTGAACTCTTGG
GR-1C3 Turner 2005 53 2 CTTAAATAGGGGCTCTCCCC CAGTGGATGCTGAACTCTTGG
GR-1D Turner 2005 54–58 3 ACAACCTTTCCCAGAGTC CAGTGGATGCTGAACTCTTGG
GR-1E Turner 2005 53–62 2 CGTGCAACTTCCTTCGAGT CAGTGGATGCTGAACTCTTGG
GR-1F Turner 2005 55–60 3 GTAGCGAGAAAAGAAACTGG CAGTGGATGCTGAACTCTTGG
GR-1H Turner 2005 59 4 CTGACAGCCCGCAACTTGGA CAGTGGATGCTGAACTCTTGG
doi:10.1371/journal.pone.0031720.t003
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Rad) at 100 V for 30 or 120 min. Blots were probed with anti-
GRa primary antibody (1:2000 dilution in 5% skim milk, sc-
1002X, Santa Cruz Biotechnology, Santa Cruz, CA), followed by
goat anti-rabbit secondary (1:2000; Millipore, Billerica, MA). After
stripping (stripping buffer: 25 mM glycine, 1.5% sodium dodecyl
sulfate, pH 2.0), blots were incubated with anti-b-actin primary
antibody (1:10 000; MAB1501, Millipore), followed by goat anti-
mouse secondary (1:5000; Millipore).
All blots were imaged using the Chemidoc XRS Molecular
Imager (Bio-Rad). A shorter exposure time (10 s) was used to
quantify the abundant 67 kDa IR band, whereas a longer
exposure time (90 s) was used to quantify total GRa protein and
all other IR bands. All GRa IR bands were within a linear range
of detection. Duplicate samples were run in separate experimental
runs. Within each run the total intensity of each immunoreactive
band was normalised to an internal control (pooled sample from
entire cohort) loaded onto the same gel, and to the b-actin band
detected in the same lane. Population outliers in each diagnostic
group were excluded if the sample normalised quantity value was
greater than 2 standard deviations from the group mean. The
geometric mean of both runs was then calculated, expressed as a
percentage of the control mean for each band. A minimum of 33
cases per diagnostic group for each immunoreactive band were
analysed. Overall, the internal standard displayed an average
variability of +/211.5% from blot-to-blot. The methods and data
from western blotting experiments analysed in this study have
been previously described [3].
Statistical analysis
All data were normally distributed. For all mRNA measures,
Pearson correlation analyses were conducted with possible
confounding demographic factors including age, pH, PMI and
RIN, and additionally within schizophrenia and bipolar disorder
cases on age-of-onset, duration-of-illness and fluphenazine-equiv-
alent antipsychotic drug measures. If significant correlations with
demographic variables were observed, analysis of covariance
(ANCOVA) was used with significantly correlated demographic
variables as covariates, to identify effects of diagnosis, gender,
manner of death, and antidepressant use. Planned comparisons of
schizophrenia, bipolar disorder and control groups were made
using Fisher’s LSD post-hoc test. Analyses of variance (ANOVAs)
were used if no correlations were seen. Two-way ANOVAs were
also used, with diagnosis, genotype and smoking status as
independent factors, to identify the effects of genotype and
smoking on mRNA expression, and also identify any genotype-
diagnosis interactions. For SNPs rs6190 and rs6196, which had
genotype groups containing fewer than five cases, non-parametric
tests (Mann-Whitney U-tests and Kruskal-Wallis tests) were used
to identify group differences in mRNA expression according to
genotype.
Genotyping
Eleven coding, promoter or putative functional single nucleotide
polymorphisms (SNPs) in the NR3C1 gene were chosen for
genotyping (Table 4). Genotyping was performed at the Australian
Genome Research Facility, with 20 ng of genomic DNA, in a
multiplex assay using a Sequenom MassArray, Autoflex Spec-
trometer and iPLEX GOLD chemistry. The pass rate for
genotyped samples was 99.0%. Genotyping of one SNP,
rs10482605 (NR3C1-1), failed to produce any results. PLINK
software (version 1.06, http://pngu.mgh.harvard.edu/purcell /
plink) [49] was used for Hardy-Weinberg equilibrium testing.
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Table 4. Taqman primers/probes used for qPCR analysis of pan GR mRNA and GR exon 1 mRNA transcript variants. HK-
housekeeping gene.
Taqman
accession
probe
location
(exon
boundary)
assay
function forward primer sequence probe sequence reverse primer sequence
ACTB Hs99999903_m1 1 - 1 HK - - -
B2M Hs99999907_m1 2 - 3 HK - - -
TBP Hs00427620_m1 2 - 3 HK - - -
UBC Hs00824723_m1 1 - 2 HK - - -
pan GR Hs00230818_m1 7 - 8 target gene - - -
GR-1B Hs01005211_m1 1 - 2 target gene - - -
GR-1C Hs01010775_m1 1 - 2 target gene - - -
GR-1D Hs03666144_m1 1 - 2 target gene - - -
GR-1E - 1 - 2 target gene CGCTGGAGGTTTTGCATTTGG CCTTCGAGTTGATATTCAC CAGGAGTTAATGATTCTTTGGAGTCCAT
GR-1F - 1 - 2 target gene CCGCCGCCACCCTTT TATCAACCCCCAACTCCC CAGGAGTTAATGATTCTTTGGAGTCCAT
GR-1H - 1 - 2 target gene GCGTGTCGGAGAGAGAACT TCCATCAGTGAATATCAACTGTT GGGTTTTCTTCTCTACCAGGAGTTA
doi:10.1371/journal.pone.0031720.t004
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